Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached [Yahoo! Finance]
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: Yahoo! Finance
hedge funds . On February 26, Argenx reported earnings for 2025, achieving its first year of annual operating profitability with $4.2 billion in net product sales, a 90% increase over 2024. This growth was fueled by the global adoption of VYVGART, which reached 19,000 patients by year-end. Management highlighted the successful launch of the prefilled syringe as a significant driver of demand, contributing to a surge of 1,000 new prescribers since its introduction. In clinical developments, the company announced positive results from the Phase III ADAPT-OCULUS study for ocular Myasthenia Gravis/MG. The study met its primary endpoint, showing statistically significant improvements in patient-reported ocular symptoms like double vision and drooping eyelids. With a PDUFA date for seronegative MG set for May 10, and plans to file for the ocular MG indication, Argenx aims to establish the broadest MG label in the industry, targeting an addressable US population of ~60,000 patients. For
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenex (ARGX) was upgraded by Deutsche Bank Aktiengesellschaft from "hold" to "buy".MarketBeat
- argenex (ARGX) had its "outperform" rating reaffirmed by Wedbush. They now have a $1,000.00 price target on the stock.MarketBeat
- Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock [Yahoo! Finance]Yahoo! Finance
- argenex (ARGX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARGX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "buy" to "hold"MarketBeat
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of PipelineGlobeNewswire
ARGX
Earnings
- 2/26/26 - Beat
ARGX
Sec Filings
- 3/6/26 - Form 6-K
- 2/26/26 - Form 6-K
- 2/26/26 - Form 6-K
- ARGX's page on the SEC website